Gerald J. Gleich

Gerald J. Gleich, MD is a Research Professor in Dermatology and Adjunct Professor in Pediatrics at the University of Utah, specializing in eosinophil-associated diseases including asthma, eosinophilic esophagitis, and hypereosinophilic syndromes. Board-certified in Allergy & Immunology and Internal Medicine, he maintains an active clinical practice at Midvalley Health Center in Murray, Utah, where patient testimonials describe him as a "treasure" and "the doctor of doctors" for his relentless dedication to patient care.

His educational foundation includes:

• B.A. in Premedical Sciences from University of Michigan
• M.D. from University of Michigan
• Internship in Medicine at Philadelphia General Hospital
• Residency in Internal Medicine at Jackson Memorial Hospital
• Fellowship in Allergy & Immunology at Strong Memorial Hospital

With over 70 years of pioneering work, Dr. Gleich is globally recognized as the "father of eosinophil research." His investigations into eosinophil biology and inflammatory mechanisms have revolutionized understanding of eosinophil-mediated diseases. His research directly enabled life-saving biologic therapies like mepolizumab and benralizumab for hypereosinophilic syndromes, while his studies on eosinophil granule proteins established fundamental diagnostic and therapeutic frameworks for eosinophilic disorders.

Analysis of his 15 most recent publications reveals three dominant research trajectories: (1) clinical validation of biologic therapies targeting IL-5 pathways for eosinophilic disorders, (2) development of novel diagnostic assays for eosinophil activity in gastrointestinal and respiratory diseases, and (3) mechanistic exploration of eosinophil functions in tissue remodeling and immune regulation. His work bridges basic immunology with clinical applications across allergy, hematology, and gastroenterology.

Though formal awards aren't enumerated in source materials, patient comments unanimously highlight his extraordinary clinical impact, noting he "instrumental[ly] help[s] bring life saving drugs to the market" and has "saved [their] life." His contributions extend beyond publications to 15 patents on eosinophil-targeted treatments.

Dr. Gleich actively mentors trainees through the University of Utah's Allergy/Immunology division, though specific advisees aren't documented. His research is sustained through collaborations with national consortia like CEGIR/TIGERs and participation in multi-center clinical trials for eosinophilic disorders. Current work focuses on elucidating eosinophil roles in normal physiology and refining diagnostic criteria for eosinophil-associated syndromes.

He leads research within the Allergy/Immunology division of Pediatrics, maintaining strong ties to clinical teams at University Health Care while continuing translational investigations into eosinophil-targeted therapeutics.